HTB South

PK and drug interactions

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

Dolutegravir pharmacokinetics in pregnancy

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

World Health Organisation paediatric dosing tool

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Featured Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Pharmacokinetic targets for efavirenz might be too high

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Paediatric TB: glimpses of PK data and a potential new approach to drug development

Efavirenz interaction studies with TB compounds bedaquiline and delamanid

Ritonavir significantly increases exposure to colchicine (gout)

Ritonavir interaction with quinine is clinically insignificant but may warrant caution

Case report: fluticasone, fluconazole and ritonavir interactions

Pharmacokinetics of old and new TB Drugs

Studies on pipeline ARVs: Quad, evitegravir/cobicistat, cobicistat, GSK1265744, BMS986001, dolutegravir, GSK-1265744, long acting formulations (monthly injections): rilpivirine-LA, raltegravir

Washout pharmacokinetics of transplacental raltegravir in neonates

Interactions between malaria drugs and etravirine or darunavir/r

Antimalarial amodiaquine and nevirapine

Atazanavir/ritonavir plus raltegravir

Atazanavir/ritonavir and voriconazole not to be coadministered

Milk thistle (silymarin) and darunavir/ritonavir

Echinacea and etravirine

Warfarin and ARVs: impact of African American race and ritonavir

Darunavir use during pregnancy

Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients

Ritonavir levels reduced with high fat meal

Monitoring kidney function change with cobicistat

Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily

Switching to 50mg ritonavir dose for selected protease inhibitors

Interactions between nevirapine and antimalarials (artemether and lumefantrine)

Interactions between antiretrovirals and complementary and African traditional medicines

Drug interactions between sirolimus (rapamycin) and ARVs

Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART

Dolutegravir (S/GSK1349572) with multivitamins or acid reducing agents

Case Reports – Cushing’s syndrome with atazanavir/ritonavir

Lopinavir and rifampicin interaction in HIV-positive patients

No interaction between raltegravir and oral contraceptives

Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children

Sports supplements impact on serum creatinine and eGFR markers of renal function

Alcohol and marijuana may reduce drug levels of atazanavir and efavirenz

Pharmacokinetics of atazanavir/ritonavir during pregnancy

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Interactions between ARVs and antimalarials atovaquone and proguanil

Efavirenz-related studies: genetics, smoking and TDM

Atazanavir: a suitable case for TDM?

A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

Bioavailability of Thai generic lopinavir/ritonavir

Recent reports on new drug interactions